Urinary gonadotropin peptide (UGP) in Egyptian patients with benign and advanced malignant urological disease.
Urinary gonadotropin peptide (UGP) levels were determined in urine samples from 450 Egyptian subjects to determine its relative level of expression in benign and malignant urological disease, and normal individuals. The mean UGP level in patients with bladder cancer was 44-fold higher than in patients with benign disease, and 81-fold higher than in normal individuals. At specificities of 95% and 100%, overall sensitivities of 73% and 60%, respectively, were observed for the detection of malignant disease. Mean UGP levels in patients with bladder cancer were significantly correlated with the stage and grade of malignant disease but did not vary significantly when stratified according to histological type of disease, nodal involvement or bilharzial association. UGP could be a potentially useful marker for the differentiation of benign from malignant urological disease.
el-Ahmady
O
O
Tumor Marker Oncology Research Center, Al-Azhar University, Cairo, Egypt.
Halim
A B
AB
Mansour
O
O
Salman
T
T
el-Din
A G
AG
Walker
R P
RP
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000652:urine*; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000652:urine*; D003937:Diagnosis, Differential; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010446:Peptide Fragments / Q000652:urine*; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000652:urine*; D014570:Urologic Diseases / Q000175:diagnosis / Q000652:urine*
D014408:Biomarkers, Tumor; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments; C063554:urinary gonadotropin fragment